News
Navigo and Mannin agree to develop a novel drug for treating COVID-19
Navigo and Mannin have entered into an agreement to develop a ‘precision X’ affinity ligand against the fusion protein of angiopoietin-1 and complement 4 binding protein (Ang1-C4bp) for use in manufacturing.